<DOC>
	<DOCNO>NCT01270932</DOCNO>
	<brief_summary>Primary : • To validate initial dose recommendation newly diagnose MM ( Mutiple Myeloma ) patient various degree renal failure use pharmacokinetic study Secondary : - To evaluate safety lenalidomide dexamethasone induction therapy newly-diagnosed MM ( Multiple Myeloma ) patient renal dysfunction use modify dose guideline - To evaluate clinical response lenalidomide dexamethasone 4 cycle use modified dose guideline - To evaluate ability collect stem cell 4 cycle lenalidomide dexamethasone induction therapy MM ( Multiple Myeloma ) patient renal failure</brief_summary>
	<brief_title>Lenalidomide &amp; High Dose Dexamethasone Untreated Multiple Myeloma Renal Failure Patients</brief_title>
	<detailed_description>STUDY DESIGN : This single institution open label , pharmacokinetic validation study combination lenalidomide dexamethasone firstline induction therapy transplant-eligible MM ( Multiple Myeloma ) patient various degree renal failure . There 4 patient group various degree renal function ( base creatinine clearance calculate 24 hour urine collection requirement dialysis ) . Each group receive lenalidomide dose per official recommend guideline : Group 1 Normal { CrCl ( creatinine clearance ) &gt; 60 mL/min } 25 mg ( full-dose ) -Daily 21 day 28 Day cycle1 Group 2 Moderate renal impairment { 30 ≤ CrCl ( creatinine clearance ) &lt; 60 mL/min } 10 mg Daily 21 day 28 day cycle Group 3 Severe renal impairment { CrCl ( creatinine clearance ) &lt; 30 mL/min , require dialysis } 15 mg Every 48 hour 21 day 28 day cycle ( 11 PLANNED DOSES EACH 28 DAY CYCLE ) Group 4 End-stage renal failure { CrCl ( creatinine clearance ) &lt; 30 mL/min , require dialysis } 5 mg Once daily 21 day 28 day cycle On dialysis day dose administer following dialysis . Pharmacokinetic ( PK ) study : We evaluate PK study follow single multiple dos lenalidomide Cycle 1.Patients receive first dose lenalidomide ( Cycle 1 , day 1 ) per designate patient group . PK ( pharmacokinetic ) sample 1st dose drawn 0 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 24 hour post-dose group 1 0 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 24 , 48 , 72 hour group . The 2nd dose lenalidomide administer Day 4 patient ( i.e . dos Days 2 3 ) . On Day 17 ( 14 dos lenalidomide administer ) , repeat PK sampling perform 0 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 24 hour group 1 , 2 4 ( next hemodialysis group 4 ) . Repeat PK sample group 3 perform 0 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 24 , 48 hour .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects must meet follow inclusion/exclusion criterion eligible study . Inclusion criteria Patients must fulfill follow criterion eligible admission study : 1 . Understand voluntarily sign informed consent form 2 . Age≥18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Previously untreated , symptomatic multiple myeloma define ALL 3 criterion : Monoclonal plasma cell bone marrow ≥10 % and/or presence biopsyproven plasmacytoma Monoclonal protein present serum and/or urine Myelomarelated organ dysfunction ( least one follow ) : C Calcium elevation blood ( serum calcium &gt; upper limit normal ) R Renal insufficiency ( serum creatinine &gt; 177umol/L ) A Anemia ( hemoglobin &lt; 100g/L 20g/L normal ) B Lytic bone lesion osteoporosis 5 . Eligible autologous stem cell transplantation per Princess Margaret Hospital criterion . 6 . Disease measurable serum urine M ( monoclonal ) protein , free light chain assay , bone marrow plasmacytosis plasmacytoma . 7 . No prior myeloma therapy ( Exception : 480 mg dexamethasone allow within past 28 day , well palliative , localized radiation therapy , without requirement washout period prior enrollment ) . 8 . ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 study entry . 9 . Laboratory test result within range : Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 50,000/mm³ ( untransfused ) Total bilirubin ≤ 22 umol/L Aspartate transaminase ( AST ) also call serum glutamic oxaloacetic transaminase ( SGOT ) Alanine transaminase ( ALT ) also call serum glutamic pyruvic transaminase ( SGPT ) ≤ 2 x ULN ( upper limit number ) ≤ 5 x ULN hepatic metastasis present . Renal function must measure 24hour urine creatinine clearance ( CrCl ) level CrCl allow eligibility . 10 . Disease free prior malignancy ≥ 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast . 11 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 25 mIU/mL ( milliInternational Units per milliliter ) within 7 14 day prior within 24 hour start lenalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP ( Females childbearing potential ) must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . 12 . Able take aspirin 81mg daily prophylactic anticoagulation [ patient intolerant ASA ( Acetyl Salicylic acid Aspirin ) may use low molecular weight heparin ] . Patients fulfill follow criterion eligible admission study : 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breastfeeding female . ( Lactating female must agree breast feed take lenalidomide ) . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Use experimental drug therapy , except 480 mg dexamethasone palliative , localize radiation therapy , without requirement washout period prior enrollment . 5 . Known hypersensitivity thalidomide . 6 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 7 . Any prior use lenalidomide . 8 . Concurrent use anticancer agent treatment . 9 . Known positive HIV ( Human immunodeficiency virus ) infectious hepatitis , type B C. 10 . Evidence AL ( amyloid light chain ) amyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>